Category: Blog

About NETRF

The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.

Blog

NETRF/NANETS award presented at NANETS 2022 meeting

After being virtual since 2020, the North American Neuroendocrine Tumor Society (NANETS) met in person for its annual meeting in Washington DC in late October. NETRF CEO Elyse Gellerman and Director of Patient Education Jessica Thomas attended the NANETS Symposium to talk with NET specialists, a number of NETRF research grantees, and other NET patient advocacy groups. They joined more than 400 attendees dedicated to better understanding neuroendocrine cancer, improving patient care, and supporting patients through advocacy and education.

Read More »
Blog

From Education to Experience: How one family’s NET experience led to better educational resources for NET patients and families.

“In 2012, my husband was diagnosed with a neuroendocrine tumor (NET) cancer. At that time, there was little information and few treatment options,” said Suzanne Ludlow, NETRF Board Member and generous benefactor of NETRF’s second edition of “Neuroendocrine Cancer: A Guide for Patients and Families.”  Suzanne lost her beloved husband Vincent in 2017, but she’s honoring his life while supporting other patients and families navigating NETs as a new member of the NETRF Board of Trustees. Read more about Suzanne and Vincent’s story here. 

Read More »
Blog

NETRF-funded Research Sets the Stage for Study Exploring Use of Terbium-161 in NETs

A new clinical trial being conducted at a single center in Switzerland aims to explore a therapy using a novel somatostatin receptor subtype 2 antagonist labelled with Terbium-161 (161Tb-DOTA-LM3). The study is sponsored by University Hospital, Basel, in collaboration with the Swiss National Science Foundation and the Paul Sherrer Institute and builds upon research funded by NETRF.

Read More »
Blog

Study Focuses on Matching Patients with Rare Cancers and Cancer of Unknown Primary to Targeted Treatments

A patient advocacy-led clinical research study aims to determine if patients who have rare tumors can benefit from matched molecular therapy based on the results of their genomic profiling. Patients with neuroendocrine tumors and unknown primaries may be eligible for this study. Sponsored by the TargetCancer Foundation, in collaboration with Foundation Medicine Inc., the TCF-001 TRACK (Target Rare Cancer Knowledge) Study uses next-generation sequencing to develop a comprehensive genomic profile of each participant’s tumor as well as their plasma circulating cell-free DNA (blood).

Read More »
Blog

A Champion for NETRF

“Anything that I have done, and any impact I have made in support of NETRF is because of the lessons he taught me.” Erica Roberts, NETRF Champion Society Member

Read More »